Lymphoma - small lymphocytic lymphoma
The PBS subsidises idelalisib for patients with small lymphocytic lymphoma (SLL).
Treatment with idelalisib can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under section 85 of the National Health Act 1953 for patients with SLL.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing idelalisib.
Make all initial applications for authority approval to prescribe PBS subsidised idelalisib for the treatment of SLL in writing and either:
All applications must include both a completed:
- authority prescription form(s)
- Small lymphocytic lymphoma – idelalisib – Initial PBS authority application form (PB231).
This authority application form can also be used for patients who received non-PBS subsidised idelalisib for the treatment of SLL before 1 September 2017.
To apply for continuing treatment contact the PBS Complex Drugs Programs enquiry line.
For more information contact the PBS Complex Drugs Programs enquiry line.
Page last updated: 15 September 2020
This information was printed 10 September 2021 from https://www.servicesaustralia.gov.au/organisations/health-professionals/services/medicare/written-authority-required-drugs/drug-program-or-condition/lymphoma-small-lymphocytic-lymphoma. It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.servicesaustralia.gov.au/individuals/site-notices when using this material.